Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: methylphenidate HCl Clear all
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
View directory record Official record
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Reversal of General Anesthesia With Methylphenidate

NCT02051452
View directory record Official record
Conditions
Post Operative Cognitive Dysfunction, Emergence From Anesthesia
Interventions
Methylphenidate, Saline
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01835548
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
NT0102, Placebo
Drug
Lead sponsor
Neos Therapeutics, Inc
Industry
Eligibility
6 Years to 12 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 17, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

NCT06431256
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
4 Years to 5 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01238822
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 4 Interventional

Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)

NCT00663442
View directory record Official record
Conditions
ADHD
Interventions
OROS methylphenidate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
6 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

NCT00434213
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daytrana
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Scottsdale, Arizona • Irvine, California • San Marcos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Not applicable Interventional Results available

The Role of Apathy in Glycemic Control

NCT00844090
View directory record Official record
Conditions
Apathy, Diabetes
Interventions
methylphenidate or placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 17, 2026, 11:19 AM EDT
Recruiting Phase 1 Interventional

Psilocybin in Chronic Low Back Pain and Depression

NCT06355414
View directory record Official record
Conditions
Chronic Low-back Pain, Depression
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

NCT02470234
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 5 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD

NCT00780208
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Daytrana (methylphenidate patch)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Early Phase 1 Interventional

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

NCT02879136
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
Methylphenidate, Physical Therapy, Atomoxetine
Drug · Other
Lead sponsor
Hubert Fernandez
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

NCT04178993
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 17, 2026, 11:19 AM EDT
Not listed Phase 4 Interventional

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

NCT03781752
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Gainesville, Florida • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 17, 2026, 11:19 AM EDT
Active, not recruiting Early Phase 1 Interventional

Targeting Drug Memories With Methylphenidate

NCT05978167
View directory record Official record
Conditions
Substance Use Disorder, Cocaine Use Disorder
Interventions
Methylphenidate, Memory reconsolidation, Placebo
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
26 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate to Improve Balance and Walking in MS

NCT01896700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Precision Functional Brain Mapping in Psilocybin

NCT04501653
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Severe Childhood Aggression (The TOSCA Study)

NCT00796302
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 17, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 11:19 AM EDT
Terminated No phase listed Observational

Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics

NCT00247689
View directory record Official record
Conditions
Substance Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 17, 2026, 11:19 AM EDT
Withdrawn Not applicable Interventional

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

NCT00393562
View directory record Official record
Conditions
Parkinson's Disease
Interventions
modafinil, methylphenidate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 17, 2026, 11:19 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 17, 2026, 11:19 AM EDT